Copyright
©The Author(s) 2025.
World J Stem Cells. Aug 26, 2025; 17(8): 107480
Published online Aug 26, 2025. doi: 10.4252/wjsc.v17.i8.107480
Published online Aug 26, 2025. doi: 10.4252/wjsc.v17.i8.107480
Table 1 Mechanism of action of mesenchymal stem cells in cardiovascular diseases
Type of mesenchymal stem cells | Human/animal study | Therapeutic role of the used stem cells | Mechanism of activation/enhancing stem cell action | Ref. |
Bone marrow mesenchymal stem cells | Mice model | Paracrine secretion of pigment epithelium-derived factor | Using younger mesenchymal stem cells | [92] |
Cord blood-derived human mesenchymal stem cell | Rat model | Formation of cardiomyocyte-like cells | Induction of differentiation into cardiomyocyte-like cells | [38] |
Human mesenchymal stem cells | Canine animal model | Formation of three-dimensional spheroids | Induction of differentiation and formation of three-dimensional spheroids | [37] |
Bone marrow mesenchymal stem cells | Yorkshire swine animal model | Cardiogenesis | Not activated | [93] |
Adult human bone marrow mesenchymal stem cells | Human study | Reducing arrhythmia, promoting angiogenesis and tissue perfusion | Not activated | [40] |
Human adipose tissue derived mesenchymal stem cells | Yorkshire cross domestic pigs | Immunomodulation and promoting angiogenic | Not activated | [41] |
Rat bone marrow mesenchymal stem cells | Rat model | Immunomodulation | Cyclooxygenase-2 overexpressing cells | [42] |
Rat and human bone marrow mesenchymal stem cells | Rat model | Immunomodulation | Sug1 knockdown MSCs | [94] |
Mice bone marrow mesenchymal stem cells | Mice model and in vitro study | Immunomodulation | Not activated | [28,29] |
Human mesenchymal stem cells | Rat model and in vitro study | Immunomodulation and differentiation into smooth muscle-like cells | LL-37-activated | [35] |
Human mesenchymal stem cells | C57BL/6J mice | Inhibition of pyroptosis and immunomodulation | Not activated | [54] |
Human umbilical cord blood-derived mesenchymal stem cells | cTnT (R141W) transgenic mouse and in vitro study | Cardiac regeneration, pro-angiogenesis, antifibrosis, and anti-apoptotic | In vivo (unconditioned); in vitro (hypoxic conditioning) | [52] |
Rat bone marrow mesenchymal stem cells | Rat study | Angiogenesis and muscle regeneration | Not activated | [58] |
Human umbilical cord blood-derived mesenchymal stem cells | Mice study | Attenuating pulmonary artery remodeling | Not activated | [62] |
Wharton's jelly-derived mesenchymal stem cells | Human study (patients with ST elevation myocardial infarction) | Cardiogenesis | Not activated | [95] |
Bone marrow mesenchymal stem cells | Human study (patients with acute myocardial infarction) | Cardiogenesis, immunomodulation, and pro-angiogenesis | Autologous cells, not activated | [96] |
Adipose tissue derived mesenchymal stem cells | Rat study | Antioxidant and anti-apoptotic effect | Resveratrol activated | [97] |
Umbilical cord-derived mesenchymal stem cells | Human study | Immunomodulatory effects | Not activated | [31] |
Autologous mesenchymal stem cells or bone marrow mononuclear cells | Human study | Cardiogensis and antifibrotic | Not activated | [98] |
Bone marrow mesenchymal stem cells | Rat study (both in vivo and in vitro) | Differentiation into functional beta-cells, restoration of glucose homeostasis, and antioxidant effect | Resveratrol-activated | [99] |
Bone marrow mesenchymal stem cells | Rat study | Pro-angiogenesis, gap junction formation, and improving survival | Ang II-activated | [100] |
Bone marrow mesenchymal stem cells | Rat study | Antiapoptotic effects, pro-angiogenesis, and anti-fibrotic effects | Not-activated and resveratrol-activated | [56] |
Mesenchymal stem cells from various sources | Human and animal (diabetic rat models) | Antiapoptotic effects and improving proliferation and cell survival | Resveratrol-activated | [101] |
- Citation: ShamsEldeen AM, Hosny SA, Maghib K, Ashour H. Current perspectives on regenerative potential of mesenchymal stem cells in alleviating cardiac injuries: Molecular pathways and therapeutic enhancement. World J Stem Cells 2025; 17(8): 107480
- URL: https://www.wjgnet.com/1948-0210/full/v17/i8/107480.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v17.i8.107480